BiomX Inc.

BiomX Inc. (NYSE American: PHGE) is a clinical-stage biopharmaceutical company focused on developing phage-based therapies targeting chronic and infectious diseases via the human microbiome. The company completed its de-SPAC merger with Chardan Healthcare Acquisitions Corp in October 2019; that blank-check vehicle was sponsored by Chardan Capital Markets and conducted its initial public offering in 2018 under the healthcare sector. The Form 8-K filed in June 2020 represents post-merger current reporting activity as BiomX continued to operate as a publicly traded entity following the combination. The company is headquartered in Israel and maintains U.S. research operations. Sign up for full data on SpacDesk to access BiomX's complete filing timeline, sponsor profile, and deal analytics alongside hundreds of other SPAC transactions.